Skip to main
ACON

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion Inc has demonstrated a robust trajectory in revenue growth, with Q3 FY25 revenue reaching $18,942, reflecting a 31% year-over-year increase driven primarily by an 89% surge in Nociscan report volumes, indicative of strong market demand for its proprietary technology. The company is actively expanding its presence through strategic commercial agreements with prominent healthcare institutions, which could further enhance its market penetration and revenue stability. Notably, the increased spending on sales and marketing, particularly tied to the CLARITY trial and improvements in UK payor coverage, suggests a commitment to long-term growth and profitability potential in the healthcare technology sector.

Bears say

Aclarion Inc faces significant financial challenges, including slower-than-expected traction with both surgeons and payers, which hampers revenue growth potential for its Nociscan product. The company is also experiencing rising marketing and administrative expenses, leading to a downward revision of its FY25 earnings per share estimates, which are now projected to be substantially negative. Moreover, underlying risks such as balance sheet concerns, regulatory hurdles, and competitive pressures further contribute to a negative outlook for Aclarion's stock performance.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.